Darolutamide plus radiation for intermediate-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding darolutamide to standard radiation can better control intermediate-risk prostate cancer. It includes men whose cancer has spread nowhere else and who are newly diagnosed with “unfavorable intermediate risk” or progress to that risk group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have prostate cancer confirmed by biopsy/pathology
- Your scans show no spread to lymph nodes outside the area or to distant organs (no metastases)
- Your risk level is “unfavorable intermediate risk,” based on PSA, Gleason score, and/or tumor stage
- You can have radiation safely as judged by your doctor, and you can undergo MRI and contrast CT scans
- You are generally well enough for treatment (life expectancy at least 5 years, and performance status ECOG 0–2)
- You can give consent and agree to effective contraception during treatment and for 1 week after stopping
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
This trial tests combining radiation therapy with two hormone-blocking drugs (darolutamide and degarelix) to treat intermediate-risk prostate cancer. The goal is to see if this combination is more effective and safe than radiation alone.
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This study looks at whether combining the drug darolutamide with standard hormone therapy can help men whose prostate cancer was found in their pelvic lymph nodes after prostate removal surgery. It aims to see if this treatment helps keep the cancer from coming back.
This trial tests a new combination of two drugs given before surgery to shrink high-risk prostate cancer. The goal is to see if this approach can improve outcomes for patients whose cancer is aggressive but has not spread.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.